Hydrocodone Bitartrate

Class: Opiate Agonists
ATC Class: R05DA03
VA Class: RE301
CAS Number: 34195-34-1
Brands: Anaplex-HD Cough, Anexsia, Ceta-Plus, Codal-DH, Codiclear DH, Codimal DH, Co-Gesic, Cyndal HD, Cytuss HC, Damason-P, Detussin, Donatussin DC, Duratuss HD, Endal HD, Entuss, Entuss-D, Entuss Expectorant, G-Tuss, Histinex HC, Histinex-D, Histussin HC, Histussin-D, Hycomine Compound, Hycosin Expectorant, Hydrogesic, Hydromet, Hydromide, Hydrophene DH, Hydro-Tussin HD, Hyphed, KG-Dal HD, KG-Dal HD Plus, KG-Tuss HD, KG-Tussin, Kwelcof, Lorcet Plus, Lortab, Maxidone Cough, Nalex DH, Norco, Pneumotussin, Protuss, Protuss-D, P-V-Tussin, Reprexain, Su-Tuss-HD, Tussafed-HC, Tuss-DS, Tussend, Tuss-HC, Tussigon, Tussionex Pennkinetic, Tuss-PD, Tuss-S Expectorant, Vanex HD, Vicodin, Vicodin ES, Vicodin Tuss Expectorant, Vicoprofen, Vitussin Expectorant, Zydone

Introduction

Opiate agonist; phenanthrene derivative.^{a b c}

Uses for Hydrocodone Bitartrate

Pain

Symptomatic relief of moderate to moderately severe pain.^{a d}

Combinations of hydrocodone and NSAIAs or acetaminophen may produce additive analgesic effects because of differing mechanisms of action.^c

Cough

Symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.^b

Hydrocodone Bitartrate Dosage and Administration

Administration

Oral Administration

Administer orally.^{a b 109}

Extended-release Suspension containing Hydrocodone Polistirex and Chlorpheniramine Polistirex (Tussionex Pennkinetic)

Use a calibrated dosing device when measuring doses of the suspension.^{109 112} Use of a household teaspoon could result in overdosage, especially when pediatric doses (2.5 mL of suspension) are measured.^{109 112}

Do not give more frequently than every 12 hours; if cough is not controlled, contact clinician.¹¹²

Do not dilute with fluids or mix with other drugs; shake well prior to administration.¹⁰⁹

Dosage

Available as hydrocodone bitartrate and hydrocodone polistirex; dosage expressed in terms of hydrocodone bitartrate.^{a b c 109}

Pediatric Patients

Cough

Hydrocodone Bitartrate

Oral

Children 6–12 years of age: 2.5 mg every 4–6 hours as needed.¹⁰⁸

Extended-release Suspension containing Hydrocodone Polistirex and Chlorpheniramine Polistirex (Tussionex Pennkinetic)

Oral

Children 6–11 years of age: 2.5 mL (5 mg when expressed in terms of hydrocodone bitartrate) every 12 hours.¹⁰⁹

Children ≥12 years of age: 5 mL (10 mg when expressed in terms of hydrocodone bitartrate) every 12 hours.¹⁰⁹

Adults

Cough

Hydrocodone Bitartrate

Oral

Usual dosage is 5 mg every 4–6 hours as needed.¹⁰⁸

Extended-release Suspension Containing Hydrocodone Polistirex and Chlorpheniramine Polistirex (Tussionex Pennkinetic)

Oral

5 mL (10 mg when expressed in terms of hydrocodone bitartrate) every 12 hours.¹⁰⁹

Pain

Oral

5–10 mg every 4–6 hours as needed.^a Adjust dosage according to severity of pain and response and tolerance of the patient.^a

Nonopiate-containing analgesic fixed combinations: Nonopiate component may limit dosage of opiate component.^{117 119 120 121} Nonopiate analgesics are available in various fixed ratios with hydrocodone and also are available in many other prescription and OTC preparations; ensure that therapy is not duplicated and that nonopiate dosage does not exceed maximum recommended dosages.^{117 118 119 121}

Prescribing Limits

Pediatric Patients

Cough

Hydrocodone Bitartrate

Oral

Children 6–12 years of age: Maximum is 15 mg daily.¹⁰⁸

Extended-release Suspension Containing Hydrocodone Polistirex and Chlorpheniramine Polistirex (Tussionex Pennkinetic)

Oral

Children 6–11 years of age: Maximum 5 mL (10 mg when expressed in terms of hydrocodone bitartrate) daily.¹⁰⁹

Children ≥12 years of age: Maximum 10 mL (20 mg when expressed in terms of hydrocodone bitartrate) daily.¹⁰⁹

Adults

Cough

Hydrocodone Bitartrate

Oral

Maximum 30 mg daily.¹⁰⁸

Extended-release Suspension Containing Hydrocodone Polistirex and Chlorpheniramine Polistirex (Tussionex Pennkinetic)

Oral

Maximum 10 mL (20 mg when expressed in terms of hydrocodone bitartrate) daily.¹⁰⁹

Special Populations

Geriatric Patients

Reduce dosage in older patients.^{a b d 109}

Cautions for Hydrocodone Bitartrate

Contraindications

• 
  

  Known hypersensitivity to hydrocodone or any ingredient in the formulation.^{b 109}

  
  


• 
  

  Possible cross-sensitivity to hydrocodone if hypersensitive to other opiates.^d

  
  


• 
  

  Extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex (Tussionex Pennkinetic): Contraindicated in children <6 years of age.¹⁰⁹

  
  

Warnings/Precautions

Warnings

Respiratory Depression

Possible dose-related respiratory depression.^{b c d e 109 112}

Potential for increased viscosity of bronchial secretions and suppression of cough reflex, with subsequent respiratory insufficiency, in patients with asthma or pulmonary emphysema who indiscriminately use antitussives.^b

Overdosage and toxicity (including fatal respiratory depression) reported in adults and children receiving the extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex (Tussionex Pennkinetic).^{109 112} Patients should seek immediate medical assistance if they experience respiratory depression.^{109 112} (See Advice to Patients.)

CNS Depression

Performance of activities requiring mental alertness and physical coordination may be impaired.^{b c d e 109}

Concurrent use of other CNS depressants may potentiate CNS depression.^{b d e 109} (See Specific Drugs under Interactions.)

Abuse Potential

Possible tolerance, psychologic dependence, and physical dependence following prolonged administration.^{b c d e 109} Use only with careful surveillance in patients with a history of drug or alcohol dependence or abuse.^{d e}

Sensitivity Reactions

Sulfite Sensitivity

Some formulations contain sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.^b

Tartrazine Sensitivity

Some formulations may contain the dye tartrazine (FD&C yellow No. 5), which may cause allergic reactions including bronchial asthma in susceptible individuals.^b Although the incidence of tartrazine sensitivity is low, it frequently occurs in patients who are sensitive to aspirin.^{100 101 102 103 104}

General Precautions

Increased Intracranial Pressure or Head Trauma

Potential for increased respiratory depressant effects and elevation of CSF pressure in patients with increased intracranial pressure, head trauma, or other intracranial lesions.^{b c d e 109}

Adverse effects of opiates may obscure the existence, extent, or course of intracranial pathology.^{b c d e 109}

Acute Abdominal Conditions

Administration may complicate assessment of patients with acute abdominal conditions.^{d e 109} Reduce initial dosage in patients who have undergone GI surgery.

Obstructive Bowel Disease

Use may result in obstructive bowel disease, especially in patients with underlying intestinal motility disorder.¹⁰⁹

Postoperative Patients

Suppression of cough reflex following thoracotomy or laparotomy may lead to postoperative retention of secretions; cautious use recommended.^{b 109}

Debilitated and Special Risk Patients

Use with caution in debilitated patients and in those with hypothyroidism, Addison’s disease, prostatic hypertrophy, urethral stricture, or pulmonary disease.^{b c d e 109}

Fixed-Combination Preparations

When used in fixed combination with other drugs, consider the cautions, precautions, and contraindications associated with the other drug(s).^a

Specific Populations

Pregnancy

Category C.^{d e 109}

Lactation

Not known whether hydrocodone is distributed into milk.^{d 109} Discontinue nursing or the drug.^{d 109}

Pediatric Use

Safety and efficacy for the management of moderate to moderately severe pain has not been established.^d

Safety and efficacy as an antitussive not established in children <6 years of age.^{105 106 107 108 109 112}

Extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex (Tussionex Pennkinetic): Contraindicated in children <6 years of age; use with caution in children ≥6 years of age due to the risk of respiratory depression.^{109 112} Risk of potentially fatal respiratory depression is increased with overdosage or concomitant use of other respiratory depressants.¹⁰⁹ (See Warnings/Precautions and see Dosage and Administration.)

Benefit-to-risk ratio should be carefully considered, especially in children with respiratory embarrassment (e.g., croup).¹⁰⁹

Risk of overdosage and toxicity (including death) in children <2 years of age receiving preparations containing antihistamines, cough suppressants, expectorants, and nasal decongestants alone or in combination for relief of symptoms of upper respiratory tract infection.^{110 111} Limited evidence of efficacy for these preparations in this age group; appropriate dosages not established.¹¹⁰ Therefore, FDA recommends not to use such preparations in children <2 years of age; safety and efficacy in older children currently under evaluation. Because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations recently agreed to voluntarily revise the product labeling to state that such preparations should not be used in children <4 years of age. During the transition period, some preparations on pharmacy shelves will have the new recommendation (“do not use in children <4 years of age”), while others will have the previous recommendation (“do not use in children <2 years of age”). FDA recommends that parents and caregivers adhere to dosage instructions and warnings on the product labeling that accompanies the preparation and consult a clinician about any concerns. Clinicians should ask caregivers about use of OTC cough/cold preparations to avoid overdosage.

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.^{d 109} Use with caution.^{d 109} (See Geriatric Patients under Dosage and Administration.)

Hepatic Impairment

Use with caution in severe hepatic impairment.^{d 109}

Renal Impairment

Use with caution in severe renal impairment.^{d 109}

Common Adverse Effects

Lightheadedness, dizziness, sedation, nausea, vomiting.^{b d 109} Adverse effects occur infrequently with usual oral antitussive dosages.^b

Interactions for Hydrocodone Bitartrate

Specific Drugs

Drug	Interaction	Comments
Anticholinergic agents	Possible paralytic ileuse 109
Antidepressants, MAO inhibitors and tricyclics	Potentiation of antidepressant adverse effectd e 109	Use with caution; reduce dosage of hydrocodonee
CNS depressants (e.g., alcohol, antihistamines, general anesthetics, opiate agonists, phenothiazines, sedatives/hypnotics, tranquilizers)	Additive CNS effectsd 109	Reduce dosage of one or both agentsd e 109

Hydrocodone Bitartrate Pharmacokinetics

Absorption

Bioavailability

Well absorbed from the GI tract following oral administration.^b

Conventional (immediate-release) preparations: Peak serum concentrations of hydrocodone occur after 1.3 hours.^{b d e}

Extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex (Tussionex Pennkinetic): Peak plasma concentrations of hydrocodone occur after 3.4 hours.¹⁰⁹

Duration

Conventional (immediate-release) preparations: Antitussive action is maintained for 4–6 hours.^b

Extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex (Tussionex Pennkinetic): Symptom control maintained for up to 12 hours.¹⁰⁹

Distribution

Extent

Distributed into skeletal muscle, kidneys, liver, intestinal tract, lungs, spleen, and brain.^c

Not known whether distributed into milk.^{d 109}

Readily crosses the placenta.^c

Elimination

Metabolism

Metabolized in the liver.^b

Elimination Route

Excreted mainly in the urine.^b

Half-life

3.8 hours.^{d e 109}

Stability

Storage

Oral

Tablets

Tight, light resistant containers at 15–30°C.^d

Solution

Tight, light resistant containers at 15–30°C.^e

Extended-release Suspension

Tussionex Pennkinetic: Tight containers at 20–25ºC (may be exposed to 15–30°C).¹⁰⁹ Shake well before use.¹⁰⁹

ActionsActions

• 
  

  Principal pharmacologic effects are on CNS and intestines.^c

  
  


• 
  

  Mild analgesic effect.^a Acts at several sites within the CNS involving several systems of neurotransmitters to produce analgesia; precise mechanism of action not fully elucidated.^c

  
  


• 
  

  Suppresses cough reflex by direct effect on cough center in medulla of brain.^{b 109}

  
  


• 
  

  Exerts drying effect on respiratory tract mucosa and increases viscosity of bronchial secretions.^b

  
  


• 
  

  Antitussive activity is slightly greater than that of codeine (on a weight basis).^b

  
  

Advice to Patients

• 
  

  Importance of not exceeding the recommended dosage.¹⁰⁹

  
  


• 
  

  Consequences of overdosage may include potentially fatal respiratory depression.¹⁰⁹

  
  


• 
  

  Importance of seeking medical attention if trouble breathing, slow heartbeat, severe sleepiness, dizziness, confusion, or cold, clammy skin develops.^{109 112}

  
  


• 
  

  When the extended-release oral suspension containing hydrocodone polistirex and chlorpheniramine polistirex (Tussionex Pennkinetic) is used, importance of ensuring that the correct amount of medication required for the intended dose is administered (e.g., importance of using a calibrated dosing device).¹⁰⁹

  
  


• 
  

  Potential for drug to impair mental alertness or physical coordination; use caution when driving or operating machinery until effects on individual are known.^{b c d e 109}

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and alcohol consumption.^{d e} Importance of avoiding alcohol-containing beverages or products.^d

  
  


• 
  

  Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.^{d e 109}

  
  


• 
  

  Importance of advising patients of other important precautionary information.^{d e 109} (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Subject to control under the Federal Controlled Substances Act of 1970 as schedule III (C-III) drugs when available as a fixed-combination preparation in a concentration of ≤15 mg per dosage unit or 5 mL combined with a therapeutic amount of one or more nonopiate drugs or with a fourfold or greater quantity of isoquinolone opium alkaloid.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Hydrocodone Bitartrate Combinations

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	5 mg with Acetaminophen 500 mg*	Ceta-Plus (C-III)	Seatrace
			Hydrocodone Bitartrate and Acetaminophen Capsules (C-III)
			Hydrogesic (C-III)	Edwards
	Solution	1.67 mg/5 mL with Chlorpheniramine Maleate 2 mg/5 mL and Phenylephrine Hydrochloride 5 mg/5 mL	Cyndal HD Syrup (C-III)	Cypress
			Hydrocodone Bitartrate Chlorpheniramine Maleate and Phenylephrine Hydrochloride Liquid (C-III)
			Hydrocodone HD Syrup (C-III)	Morton Grove
			KG-Dal HD Syrup (C-III)	King
			Tuss-PD (C-III)	Seatrace
			Vanex HD (C-III)	Jones Pharma
		1.67 mg/5 mL with Phenylephrine Hydrochloride 5 mg/5 mL	Nalex DH (C-III)	Blansett
		1.67 mg/5 mL with Phenylephrine Hydrochloride 5 mg/5 mL and Pyrilamine Maleate 8.33 mg/5 mL	Codal-DH Syrup (C-III)	Cypress
			Codimal DH Syrup (C-III)	Schwarz
			Hydrophene DH Syrup (C-III)	Morton Grove
		1.7 mg/5 mL with Brompheniramine Maleate 2 mg/5 mL and Pseudoephedrine Hydrochloride 30 mg/5 mL	Anaplex-HD Cough Syrup (C-III)	ECR
		2 mg/5 mL with Chlorpheniramine Maleate 2 mg/5 mL and Phenylephrine Hydrochloride 5 mg/5 mL	Endal HD Syrup (C-III)	Propst
		2.5 mg/5 mL with Acetaminophen 167 mg/5 mL	Hydrocodone Bitartrate and Acetaminophen Elixir (C-III)
			Lortab Elixir (C-III)	UCB
		2.5 mg/5 mL with Chlorpheniramine Maleate 2 mg/5 mL and Phenylephrine Hydrochloride 5 mg/5 mL	Cytuss HC Syrup (C-III)	Cypress
			Histinex HC (C-III)	Ethex
			Histussin HC Syrup (C-III)	Sanofi-Synthelabo
			Hydrocodone CP Syrup (C-III)
			KG-Dal HD Plus Syrup (C-III)	King
			Tuss-HC (C-III)	Seatrace
		2.5 mg/5 mL with Chlorpheniramine Maleate 2 mg/5 mL and Pseudoephedrine Hydrochloride 30 mg/5 mL	Hyphed Syrup (C-III)	Cypress
			KG-Tussin Syrup (C-III)	King
			P-V-Tussin Syrup (C-III)	Numark
			Tussend Syrup (C-III)	Monarch
		2.5 mg/5 mL with Guaifenesin 50 mg/5 mL and Phenylephrine Hydrochloride 7.5 mg/5 mL	Donatussin DC Syrup (C-III)	Laser
			Tussafed-HC (C-III)	Everett
		2.5 mg/5 mL with Guaifenesin 100 mg/5 mL and Pseudoephedrine Hydrochloride 30 mg/5 mL	Duratuss HD Elixir (C-III)	UCB
			Hydro-Tussin HD Elixir (C-III)	Ethex
			KG-Tuss HD Elixir (C-III)	King
			Su-Tuss-HD Elixir (C-III)	Cypress
			Tussend Expectorant (C-III)	Monarch
		2.5 mg/5 mL with Guaifenesin 200 mg/5 mL	Pneumotussin 2.5 Cough Syrup (C-III)	ECR
		3.5 mg/5 mL with Chlorpheniramine Maleate 2 mg/5 mL and Phenylephrine Hydrochloride 5 mg/5 mL	Endal HD Plus Syrup (C-III)	Propst
		5 mg/5 mL with Chlorpheniramine Maleate 2 mg/5 mL and Phenylephrine Hydrochloride 5 mg/5 mL	Tuss-DS (C-III)	Seatrace
		5 mg/5 mL with Guaifenesin 100 mg/5 mL	Codiclear DH Syrup (C-III)	Schwarz
			G-Tuss Syrup (C-III)	Seatrace
			Hycosin Expectorant (C-III)	Alpharma
			Hydrocodone Bitartrate and Guaifenesin Expectorant (C-III)
			Hydrocodone GF Syrup (C-III)	Morton Grove
			Kwelcof Liquid (C-III)	Ascher
			Vicodin Tuss Expectorant Syrup (C-III)	Abbott
			Vitussin Expectorant (C-III)	Cypress
		5 mg/5 mL with Homatropine Methylbromide 1.5 mg/5 mL	Hydrocodone Bitartrate and Homatropine Methylbromide Syrup (C-III)
			Hydromet Syrup (C-III)	Alpharma
			Hydromide Syrup (C-III)	Major
		5 mg/5 mL with Potassium Guaiacolsulfonate 300 mg/5 mL	Entuss Expectorant (C-III)	Lee
			Protuss (C-III)	First Horizon
		5 mg/5 mL with Potassium Guaiacolsulfonate 300 mg/5 mL and Pseudoephedrine Hydrochloride 30 mg/5 mL	Entuss-D Liquid (C-III)	Lee
			Protuss-D (C-III)	First Horizon
		5 mg/5 mL with Pseudoephedrine Hydrochloride 60 mg/5 mL	Detussin Liquid (C-II)	Alpharma
			Histinex-D (C-III)	Ethex
			Histussin-D (C-III)	Sanofi-Synthelabo
			Tuss-S Expectorant (C-III)	Seatrace
		10 mg/5 mL with Potassium Guaiacolsulfonate 400 mg/5 mL	Protuss (C-III)	First Horizon
	Tablets	2.5 mg with Acetaminophen 500 mg	Hydrocodone Bitartrate and Acetaminophen Tablets (C-III)
			Lortab (C-III; scored)	UCB Pharma
		2.5 mg with Guaifenesin 300 mg	Pneumotussin (C-III)	ECR
		5 mg with Acetaminophen 250 mg, Caffeine Anhydrous 30 mg, Chlorpheniramine Maleate 2 mg, and Phenylephrine Hydrochloride 10 mg	Hycomine Compound (C-III; scored)	Endo
		5 mg with Acetaminophen 400 mg*	Zydone (C-III)	Endo
		5 mg with Acetaminophen 500 mg*	Anexsia 5/500 (C-III; scored)	Mallinckrodt
			Co-Gesic (C-III; scored)	Schwarz
			Lortab 5/500 (C-III; scored)	UCB
			Vicodin (C-III; scored)	Abbott
		5 mg with Aspirin 500 mg	Damason-P (C-III)	Mason
		5 mg with Chlorpheniramine Maleate 4 mg and Pseudoephedrine Hydrochloride 60 mg	Tussend (C-III)	Monarch
		5 mg with Guaifenesin 300 mg	Entuss (C-III)	Lee
		5 mg with Homatropine Methylbromide 1.5 mg	Tussigon (C-III; scored)	Jones Pharma
		5 mg with Pseudoephedrine Hydrochloride 60 mg	P-V-Tussin (C-III; scored)	Numark
		7.5 mg with Acetaminophen 400 mg*	Zydone (C-III)	Endo
		7.5 mg with Acetaminophen 500 mg*	Lortab (C-III; scored)	UCB
		7.5 mg with Acetaminophen 650 mg*	Anexsia 7.5/650 (C-III; scored)	Mallinckrodt
			Lorcet Plus (C-III; scored)	Forest
		7.5 mg with Acetaminophen 750 mg*	Vicodin ES (C-III; scored)	Abbott
		10 mg with Acetaminophen 325 mg	Hydrocodone Bitartrate and Acetaminophen Tablets (C-III)
			Norco (C-III; scored)	Watson
		10 mg with Acetaminophen 400 mg	Zydone (C-III)	Endo
		10 mg with Acetaminophen 500 mg*	Lortab 10/500 (C-III; scored)	UCB
		10 mg with Acetaminophen 650 mg*	Lorcet 10/650 (C-III; scored)	Forest
		10 mg with Acetaminophen 660 mg	Anexia 10/660 (C-III)	Mallinckrodt
			Vicodin HP (C-III; scored)	Abbott
		10 mg with Acetaminophen 750 mg	Maxidone 2.5 Cough Syrup (C-III)	Watson
	Tablets, film-coated	2.5 mg with Ibuprofen 200 mg	Reprexain (C-III)	Hawthorn
		5 mg with Ibuprofen 200 mg	Reprexain (C-III)	Hawthorn
		7.5 mg with Ibuprofen 200 mg*	Hydrocodone Bitartrate and Ibuprofen Film-coated Tablets (C-III)
			Vicoprofen (C-III)	Abbott
		10 mg with Ibuprofen 200 mg	Reprexain (C-III)	Hawthorn

Hydrocodone Polistirex Combinations

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Suspension, extended-release	equivalent to Hydrocodone Bitartrate 10 mg/5 mL with Chlorpheniramine Polistirex equivalent to Chlorpheniramine Maleate 8 mg/5 mL	Tussionex Pennkinetic (C-III)	UCB

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Hydrocodone-Acetaminophen 10-325MG Tablets (MALLINCKRODT PHARM): 30/$16.99 or 90/$44.97

Hydrocodone-Acetaminophen 10-500MG Tablets (MALLINCKRODT PHARM): 30/$14.99 or 90/$38.98

Hydrocodone-Acetaminophen 10-650MG Tablets (MALLINCKRODT PHARM): 30/$13.99 or 90/$29.97

Hydrocodone-Acetaminophen 10-660MG Tablets (MALLINCKRODT PHARM): 30/$15.99 or 90/$35.97

Hydrocodone-Acetaminophen 10-750MG Tablets (MALLINCKRODT PHARM): 30/$32.99 or 90/$89.97

Hydrocodone-Acetaminophen 2.5-500MG Tablets (QUALITEST): 30/$12.99 or 90/$27.27

Hydrocodone-Acetaminophen 5-500MG Tablets (MALLINCKRODT PHARM): 30/$11.99 or 60/$16.98

Hydrocodone-Acetaminophen 7.5-325MG Tablets (MALLINCKRODT PHARM): 30/$18.99 or 90/$51.97

Hydrocodone-Acetaminophen 7.5-500MG/15ML Solution (QUALITEST): 473/$60.98 or 1419/$182.95

Hydrocodone-Acetaminophen 7.5-500MG Tablets (MALLINCKRODT PHARM): 30/$13.99 or 60/$17.98

Hydrocodone-Acetaminophen 7.5-650MG Tablets (MALLINCKRODT PHARM): 100/$15.99 or 300/$35.97

Hydrocodone-Acetaminophen 7.5-750MG Tablets (MALLINCKRODT PHARM): 30/$12.99 or 90/$23.99

Lorcet 10/650 10-650MG Tablets (FOREST): 30/$57.99 or 90/$159.97

Lorcet Plus 7.5-650MG Tablets (FOREST): 30/$48.49 or 90/$131.14

Lortab 7.5-500MG/15ML Elixir (UCB PHARMA): 120/$40.99 or 360/$115.97

Lortab 10 10-500MG Tablets (UCB PHARMA): 30/$55.99 or 90/$150.97

Lortab 2.5 2.5-500MG Tablets (UCB PHARMA): 30/$30.99 or 90/$78.97

Lortab 5 5-500MG Tablets (UCB PHARMA): 30/$54.99 or 90/$140.97

Lortab 7.5 7.5-500MG Tablets (UCB PHARMA): 30/$54.99 or 90/$145.96

Norco 10-325MG Tablets (WATSON LABS): 30/$64.29 or 90/$178.55

Norco 5-325MG Tablets (WATSON LABS): 30/$45.99 or 90/$115.97

Norco 7.5-325MG Tablets (WATSON LABS): 30/$49.99 or 90/$139.97

Stagesic 5-500MG Capsules (MAGNA PHARMACEUTICALS INC): 30/$24.99 or 90/$51.97

Vicodin 5-500MG Tablets (ABBOTT): 30/$49.99 or 90/$119.98

Vicodin ES 7.5-750MG Tablets (ABBOTT): 30/$51.9 or 90/$138.37

Vicodin HP 10-660MG Tablets (ABBOTT): 30/$51.99 or 90/$145.98

Xodol 10-300MG Tablets (VICTORY PHARMA): 100/$265.99 or 300/$749.97

Zydone 10-400MG Tablets (ENDO PHARMACEUTICALS): 30/$31.99 or 90/$83.97

Zydone 5-400MG Tablets (ENDO PHARMACEUTICALS): 30/$27.99 or 90/$65.97

Zydone 7.5-400MG Tablets (ENDO PHARMACEUTICALS): 30/$32.99 or 90/$72.58

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

Only references cited for selected revisions after 1984 are available electronically.

100. American Medical Association Council on Scientific Affairs. Aspartame: review of safety issues. JAMA. 1985; 254:400-2. [IDIS 202002] [PubMed 2861297]

101. Gossel TA. A review of aspartame: characteristics, safety and uses. US Pharm. 1984; 9:26,28-30.

102. Food and Drug Administration. Aspartame as an inactive ingredient in human drug products; labeling requirements. Proposed rule. [21 CFR Part 201] Fed Regist. 1983; 48:54993-5. (IDIS 178728)

103. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption; aspartame. Final rule. [21 CFR Part 172] Fed Regist. 1983; 48:31376-82. (IDIS 172957)

104. Anon. Aspartame and other sweeteners. Med Lett Drugs Ther. 1982; 24:1-2. [PubMed 7054648]

105. Food and Drug Administration. FDA takes action to stop marketing of unapproved hydrocodone products. Rockville, MD; 2007 Sep 28. From FDA website.

106. Food and Drug Administration. Questions and answers about FDA's enforcement action regarding unapproved hydrocodone drug products. Rockville, MD; 2007 Oct 1. From FDA website.

107. Food and Drug Administration. Drug products containing hydrocodone; enforcement action dates. Notice. [Docket No. 2007N-0353]. Fed Regist. 2007; 72:55780-4.

108. Endo Pharmaceuticals, Inc. Hycodan (hydrocodone bitartrate and homatropine methylbromide) tablets and suspension prescribing information. Chadds Ford, PA; 2001 Nov.

109. UCB, Inc. Tussionex Pennkinetic (hydrocodone polistirex and chlorpheniramine polistirex) extended-release suspension prescribing information. Smyrna, GA; 2008 Jan.

110. Srinivasan A, Budnitz D, Shehab N et al. Infant deaths associated with cough and cold medications—two states, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56:1-4. [PubMed 17218934]

111. Food and Drug Administration. Cough and cold medications in children less than two years of age. Rockville, MD; 2007 Jan 12. From FDA website.

112. Food and Drug Administration. FDA public health advisory: Important information for the safe use of Tussionex Pennkinetic extended-release suspension. Rockville, MD; 2008 Mar 11. From FDA web site.

117. Jackson KC II, Lipman AG. Nonopioid analgesics. In: Lipman AG, ed. Pain management for primary care clinicians. Bethesda, MD: American Society of Health-System Pharmacists; 2004:43-58.

118. Cranmer KW, Mason M. Special considerations in geriatric pain management. In: Lipman AG, ed. Pain management for primary care clinicians. Bethesda, MD: American Society of Health-System Pharmacists; 2004:219-232.

119. Fakata KL, Miaskowski C, Lipman AG. Chronic malignant pain. In: Lipman AG, ed. Pain management for primary care clinicians. Bethesda, MD: American Society of Health-System Pharmacists; 2004:139-52.

120. McNicol E, Carr DB. Pharmacological treatment of pain. In: McCarberg B, Passik SD, eds. Expert guide to pain management. Philadelphia: American College of Physicians; 2005:145-78.

121. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 5th edition. Glenview, IL; 2003:3,9,13,14.

a. AHFS Drug Information 2008. McEvoy GK, ed. Hydrocodone Bitartrate. Bethesda, MD: American Society of Health-System Pharmacists; 2008:2186-7.

b. AHFS Drug Information 2008. McEvoy GK, ed. Hydrocodone Bitartrate. Bethesda, MD; American Society of Health-System Pharmacists; 2008:2805-7.

c. AHFS drug information 2004. McEvoy GK, ed. Opiate agonists general statement. Bethesda, MD: American Society of Hospital Pharmacists; 2004:2030-5.

d. Watson Laboratories. Hydrocodone Bitartrate and Acetaminophen tablets prescribing information. Corona, CA; 2003 Jan.

e. Monarch Pharmaceuticals. Tussend tablets and syrup prescribing information. Bristol, TN; 1998 Sep.

More Hydrocodone Bitartrate resources

• Hydrocodone Bitartrate Drug Interactions
• Hydrocodone Bitartrate Support Group
• 0 Reviews · Be the first to review/rate this drug